Ovarian carcinoma (high-grade serous predominant) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-BRIP1-CARRIER-PREVENTION-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-19 \| pending_clinical_signoff
Diseases	`DIS-OVARIAN`
Sources	`SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025` `SRC-NCCN-OVARIAN-2025`

Notes

STUB — v0.3 moderate-penetrance panel prevention expansion. Two-Co-Lead signoff queued per CHARTER §6.1 dev-mode.

Used By

Indication

IND-BRIP1-SUSPICION-PREVENTION-TESTING - IND-BRIP1-SUSPICION-PREVENTION-TESTING